MASHINIi

CARL ZEISS MEDITEC AG.

AFX.XETRA | Manufacture of medical and dental instruments and supplies

Carl Zeiss Meditec AG is a leading global medical technology company. It supplies innovative technologies and application-oriented solutions designed to improve the diagnosis and treatment of eye diseases and other health conditions. The company offers a comprehensive portfolio of products and servi...Show More

Ethical Profile

Mixed.

Carl Zeiss Meditec aims for carbon neutrality in its operations by 2025 and uses 100% renewable energy. However, reports indicate Scope 1 & 2 emissions increased from 62,322 to 63,987 t CO₂-eq last fiscal year, with Scope 3 emissions also rising. The company demonstrates strong commitment to honest business, featuring a 'ZEISS Integrity Line' whistleblower system, a global Code of Conduct, and a €50 gift guideline to prohibit bribery; approximately 90% of ethical claims are independently verified. While dedicated to improving health through medical tech, recalls of medical devices are noted in FDA data. Reports also suggest "Animal Testing Yes" for AFX.XETRA, though specific details are limited. Waste reduction efforts include a 29% cut from 2018-2023.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business10
-100100
Kind to Animals20
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-40
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech10
-100100
Zero Waste & Sustainable Products-30
-100100

Better Health for All

0

Carl Zeiss Meditec AG's core business, including medical technology for ophthalmology and other surgical fields, is dedicated to improving the diagnosis and treatment of diseases, providing exceptional health benefits. The company has no reported revenue from products with negative health outcomes. However, Carl Zeiss Meditec AG was identified as a recalling firm for a Class 2 medical device recall by the FDA in April 2022.

1
The company provides comprehensive support for healthcare workforce capacity by offering training and continuing education for medical personnel in underprivileged regions. This includes supporting 10 scholarships for the International Ophthalmology Association (ICO) Fellowship Program between 2012-2020, enabling 2 IOFF scholarships and co-funding 3 one-year scholarships in the past four years, and financing 2 research grants with the European Association of Neurosurgical Societies (EANS) in 2022.
2
The ZEISS Research Data Platform ensures secure user-based access to data, emphasizing data security and control.
3

Fair Money & Economic Opportunity

0

Carl Zeiss Meditec AG is a medical technology company and does not offer lending, deposit, or other consumer financial services. The 'Fair Money & Economic Opportunity' value assesses financial institutions on their provision of fair financial services. Consequently, KPIs related to consumer financial products, such as `underserved_client_share`, `pricing_fairness`, `exploitative_fee_exposure`, `inclusion_initiatives`, `data_accessibility`, `fair_lending_compliance`, `wealth_building_outcome`, `financial_literacy_initiatives`, `debt_burden_ratio`, `geographic_inclusion`, and `product_simplicity`, are not applicable. The company does not have APRs, fee structures, loan books, customer financial data, or operate financial service access points to evaluate against these metrics. While the company supports social initiatives like the Aloka Vision Programme for eye care in underserved regions and general community projects through the Carl Zeiss Foundation and Promotion Fund, these are not 'community finance' reinvestments, making `profit_reinvestment` also not applicable in this context.

1

Fair Pay & Worker Respect

0

No evidence available to assess CARL ZEISS MEDITEC AG on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

Carl Zeiss Meditec has implemented the German Supply Chain Act (LkSG)

1
and the RBA Code of Conduct
2
. The company operates a Comprehensive Compliance Program based on the AdvaMed Code of Ethics
3
and maintains a Code of Conduct
4
. A 'ZEISS Integrity Line' whistleblower system is available for reporting suspected violations, including those related to human and environmental rights in the supply chain
5
. However, the provided articles do not contain specific quantitative data for fair trade certification share, audit frequency, forced or child labor incidents, traceability coverage, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend.

Honest & Fair Business

10

The company has a formal whistleblower protection policy, the 'ZEISS Integrity Line,' which allows for anonymous reporting via intranet and website.

1
It also maintains a globally applicable Code of Conduct that prohibits bribery and sets a €50 guideline for gifts and invitations.
2
The Code emphasizes compliance with various laws, including export controls, customs, tax, accounting, data privacy, and anti-money laundering, and references adherence to the Responsible Business Alliance Code of Conduct, UN Guiding Principles on Business and Human Rights, and the International Bill of Human Rights.
3

Kind to Animals

20

ZEISS Ventures has made an 8-figure investment in InSphero, a life science startup that develops 3D cell culture solutions for drug discovery and safety testing.

1
This investment is strategically aligned with the company's Life Science Industrialization initiative
2
and leverages the tailwinds from the FDA Modernization Act, which elevates alternative methods for drug development to the same level as animal testing.
3

No War, No Weapons

0

The parent ZEISS Group formally states in its reporting that involvement in activities related to controversial weapons is not material.

1
This indicates no significant exposure for the group, which includes Carl Zeiss Meditec AG, a medical technology company. No other specific, concrete evidence was found for Carl Zeiss Meditec AG regarding its involvement in arms manufacturing, military contracts, or conflict facilitation.

Planet-Friendly Business

-40

Carl Zeiss Meditec is considering joining the Science Based Targets initiative (SBTi).

1
The company has a target for carbon neutrality in its own operations (Scope 1 and 2 emissions) by 2025.
2
Total Scope 1 and 2 greenhouse gas emissions for 2023/24 were 63,987 t CO₂-eq, an increase from 62,322 t CO₂-eq in 2022/23.
3
The company achieved its 2020 targets of 50% less energy, 40% less water, and 30% less waste, relative to value added from a 2010 baseline.
4
New environmental targets for 2025 include a 20% reduction in energy, 10% in waste, and 15% in water, relative to value added from a 2019 baseline.
5
The company uses carbon offsets from Gold Standard, CER, Gold Standard VER, and Verified Carbon Standard (VCS).
6

Respect for Cultures & Communities

0

No specific data relevant to the 'Respect for Cultures & Communities' ethical value was found across the provided articles for any of the defined KPIs. The available information primarily consists of general company details, overall ESG risk ratings

1
, or explicit statements indicating a lack of data for the specific metrics
2
.

Safe & Smart Tech

10

Carl Zeiss Meditec AG holds ISO 27001 certification, indicating a strong security program

1
. The company also states compliance with major privacy regulations such as HIPAA and GDPR
2
. There are no documented incidents of unauthorized data use.

Zero Waste & Sustainable Products

-30

The company has implemented several waste reduction initiatives, including a Kanban process that reduces cardboard waste by 22-28 tonnes

1
and plastic waste by 11-18 tonnes annually
2
. New eyeglass packaging saves 68 tons of paper each year
3
, and a USA site achieved a yearly waste reduction equivalent to 2.5 million plastic bags
4
. For hazardous waste, a USA site partners with an automotive company to recycle 150 kg of spent alcohol from lens production annually
5
. The company received first place in the material efficiency category for the 2021 Umwelttechnikpreis Baden-Württemberg
6
. The company has a company-wide target to reduce waste by 10% by fiscal year 2024/25
7
, building on a 29% waste reduction achieved from 2018 to 2023
8
.

Own CARL ZEISS MEDITEC AG?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.